A recent meta-analysis of over 350,000 ambulatory patients identified that the absolute risk of diabetic ketoacidosis (DKA) associated with sodium glucose co-transporter-2 (SGLT-2) inhibitors was 0.6–2.2 events per 1000 person years. Anecdotal evidence suggests that DKA risk is higher among hospitalized patients but empiric data are lacking. Our objective was to assess the risk of DKA among hospitalized patients who received an SGLT-2 inhibitor during hospitalization.
The American Society of Anesthesiologists (ASA) recently published guidance relating to the use of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) before procedures, based mainly on anecdotal reports of retained gastric contents despite apparently appropriate periods of fasting